上海生物医药周开幕，A股最大医疗ETF（512170）溢价拉涨1%！资金押注60日均线，近3日大举增仓6.75亿元

Core Insights - The medical sector in A-shares is experiencing a significant rebound, with the largest medical ETF (512170) seeing a premium increase of over 1% and a trading volume exceeding 240 million yuan [1] - The latest scale of the ETF is 25.849 billion yuan, ranking it first among all medical ETFs in the market [1] ETF Performance - The medical ETF (512170) is currently trading at 0.377 yuan, with a rise of 0.004 yuan (1.07%) [2] - The ETF has attracted a total of 675 million yuan in the last three days, indicating strong buying interest [3] Market Trends - The Shanghai International Biopharmaceutical Industry Week, which opened on October 13, focuses on global innovation in drugs and medical devices, highlighting the expanding scale of the biopharmaceutical industry in Shanghai [5] - In 2024, 30 new domestic innovative drugs and 45 innovative medical devices are expected to be approved, representing 17% and 20% of the national totals, respectively [5] Industry Outlook - According to Xinda Securities, while the pharmaceutical and biotechnology sector is currently affected by policy fluctuations, the long-term industry trend remains positive, with Chinese innovative drug companies gaining global competitiveness [5] - Dongwu Securities notes that tariff policies have minimal impact on medical devices, and there is optimism regarding domestic substitution and self-control in the industry [5] ETF Composition - The medical ETF (512170) passively tracks the CSI Medical Index, with the top ten weighted stocks including WuXi AppTec, Mindray Medical, and others [6]